Xeljanz Development Plans Scaled Back By Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm will deprioritize development of the oral JAK inhibitor in Crohn’s disease, ankylosing spondylitis and potentially psoriasis, while focusing on expansion in psoriatic arthritis and ulcerative colitis.